Idecabtagene Vicleucel Continues to Impress in Updated ASCO Myeloma Data
Idecabtagene vicleucel elicited a median overall survival of 24.8 months with a 51% event-free rate at 24 months in patients with heavily pretreated, relapsed/refractory multiple myeloma.